GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (OTCPK:ADYX) » Definitions » Intrinsic Value: Projected FCF

Adynxx (Adynxx) Intrinsic Value: Projected FCF : $0.00 (As of May. 06, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Adynxx Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-06), Adynxx's Intrinsic Value: Projected FCF is $0.00. The stock price of Adynxx is $0.0001. Therefore, Adynxx's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Adynxx's Intrinsic Value: Projected FCF or its related term are showing as below:

ADYX's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.39
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Adynxx Intrinsic Value: Projected FCF Historical Data

The historical data trend for Adynxx's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Intrinsic Value: Projected FCF Chart

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -81.88 -71.66 -283.81 -128.60 -145.26

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -141.13 -145.26 -146.89 -36.15 -24.75

Competitive Comparison of Adynxx's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Adynxx's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adynxx's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Adynxx's Price-to-Projected-FCF falls into.



Adynxx Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Adynxx's Free Cash Flow(6 year avg) = $-13.34.

Adynxx's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Sep19)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-13.34208+-11.062/0.8)/5.808
=-24.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adynxx  (OTCPK:ADYX) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Adynxx's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0001/-24.250825175876
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adynxx Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Adynxx's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Adynxx (Adynxx) Business Description

Industry
Traded in Other Exchanges
N/A
Address
100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
Executives
Gregory J. Flesher director 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Donald C. Manning officer: CHIEF MEDICAL OFFICER C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Domain Partners Viii, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber director C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian K Halak 10 percent owner C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair 10 percent owner 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu 10 percent owner
Dennis Podlesak director C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
James G Coulter 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
David Bonderman 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102

Adynxx (Adynxx) Headlines

From GuruFocus

Market Overlooks Alliqua's First MAC Coverage

By Last Financier Last Financier 04-21-2015

Alliqua Biomedical CEO Provides Update to Shareholders

By Marketwired Marketwired 01-03-2019

Alliqua BioMedical CEO Provides Update to Shareholders

By Marketwired Marketwired 04-22-2019

Adynxx Reports Third Quarter 2019 Financial Results

By Marketwired Marketwired 11-14-2019